Loading...
•
Jun 30, 2023
Harrow Q2 2023 Earnings Report
Announced second quarter 2023 financial results, highlighting progress in positioning Harrow as a top-tier U.S.-focused ophthalmic pharmaceutical company and improved product portfolio.
Key Takeaways
Harrow announced its second quarter 2023 financial results, showcasing an improved product portfolio and progress toward achieving financial goals. The company's CEO highlighted the significant improvements in the balance sheet and the comprehensive ophthalmic pharmaceutical offerings in the U.S. market.
Harrow made progress positioning itself as a top-tier U.S.-focused ophthalmic pharmaceutical company.
The company improved its balance sheet through a series of transactions since January 2023.
Harrow dramatically improved its product portfolio, now one of the most comprehensive in the U.S.
The company believes it is on its way to achieving the highest financial goals for its stockholders.
Forward Guidance
No specific forward guidance was found in the provided document.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...